Astragaloside IV attenuates cardiac hypertrophy in rats born from mothers with intrauterine hypoxia through the PKCβII/Egr‑1 pathway

  • Authors:
    • Ying Zhang
    • Mengqi Wu
    • Yanbing Deng
    • Baomei He
    • Hong Li
  • View Affiliations

  • Published online on: June 14, 2023     https://doi.org/10.3892/etm.2023.12064
  • Article Number: 365
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Astragaloside IV (AS‑IV) is a naturally occurring agent that confers several wide‑ranging reported pharmacological effects, such as cardioprotective, antioxidative and pro‑angiogenic activities. Although it was previously reported that AS‑IV could attenuate neonatal rat myocardial ischemia‑reperfusion injury, the possible effects of AS‑IV on the development of cardiac hypertrophy associated with intrauterine hypoxia (IUH) remain unclear. The present study established a model of IHU by placing the pregnant rats in a plexiglass chamber with an oxygen supply of 10% before neonatal rat delivery. To investigate the in vivo effect of AS‑IV on cardiac hypertrophy, neonatal rats with hypertension were randomly grouped to receive AS‑IV (20 mg/kg), AS‑IV (40 mg/kg), AS‑IV (80 mg/kg) or vehicle for 12 weeks, followed by left ventricular (LV) hemodynamics and heart tissue histological analysis. Rats born from mothers with IHU displayed pathological features of cardiac hypertrophy. However, AS‑IV 40 and 80 mg/kg significantly decreased the heart/body weight (BW), LV mass (LVM)/BW, heart mass/tibia length (TL) and LVM/TL ratios. H&E staining showed that 40 and 80 mg/kg AS‑IV prevented the morphometric changes induced by IHU. According to data from LV hemodynamics measurements, AS‑IV 80 mg/kg reversed the increased systolic blood pressure, diastolic blood pressure, LV systolic pressure, LV end‑diastolic pressure, dP/dt maximum and heart rate induced by IHU. Mechanistically, ERK1/2 activation and early growth response 1 (Egr‑1) protein expression were both upregulated by IHU induction, which was reversed by AS‑IV treatment. In conclusion, these data suggested that AS‑IV could attenuate cardiac hypertrophy in neonatal rats born from mothers with IHU through the protein kinase C β type isoform 2/Egr‑1 pathway, but the underlying mechanism requires further investigation.
View Figures
View References

Related Articles

Journal Cover

August-2023
Volume 26 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang Y, Wu M, Deng Y, He B and Li H: Astragaloside IV attenuates cardiac hypertrophy in rats born from mothers with intrauterine hypoxia through the PKCβII/Egr‑1 pathway. Exp Ther Med 26: 365, 2023.
APA
Zhang, Y., Wu, M., Deng, Y., He, B., & Li, H. (2023). Astragaloside IV attenuates cardiac hypertrophy in rats born from mothers with intrauterine hypoxia through the PKCβII/Egr‑1 pathway. Experimental and Therapeutic Medicine, 26, 365. https://doi.org/10.3892/etm.2023.12064
MLA
Zhang, Y., Wu, M., Deng, Y., He, B., Li, H."Astragaloside IV attenuates cardiac hypertrophy in rats born from mothers with intrauterine hypoxia through the PKCβII/Egr‑1 pathway". Experimental and Therapeutic Medicine 26.2 (2023): 365.
Chicago
Zhang, Y., Wu, M., Deng, Y., He, B., Li, H."Astragaloside IV attenuates cardiac hypertrophy in rats born from mothers with intrauterine hypoxia through the PKCβII/Egr‑1 pathway". Experimental and Therapeutic Medicine 26, no. 2 (2023): 365. https://doi.org/10.3892/etm.2023.12064